Use of a Novel Thyroid-Stimulating Hormone Model for Predicting the Progression of Hepatocellular Carcinoma

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2020 Nov 16

PMID 33192075

Citations 1

Authors

Lihua Yu

Xiaoli Liu

Yuyong Jiang

Xinhui Wang

Xianbo Wang

Zhiyun Yang

Affiliations

Soon will be listed here.

Abstract

Background: Individuals with hepatocellular carcinoma (HCC) are at risk of tumor recurrence after surgical resection, which affects their survival. The aim of the present study was to establish a model for predicting tumor progression in patients with HCC.

Methods: To develop and validate the efficacy of a novel prognostic model, a retrospective cohort with HCC (n = 1005) at Beijing Ditan Hospital was enrolled from January 2008 and June 2017. Furthermore, a prospective cohort (n = 77) was recruited to validate the association between thyroid-stimulating hormone (TSH) levels and tumor progression in patients with HCC.

Results: The model used in predicting the progression of HCC included four variables (namely, Barcelona Clinic Liver Cancer [BCLC] stage, presence of portal vein tumor thrombus, alpha-fetoprotein level, and TSH level). The AUROC of the 1-year progression-free survival (PFS) model was 0.755 and 0.753 in the deriving cohort and validation cohort, respectively, and these values were significantly higher than those of the Child-Pugh score, Model for End-stage Liver Disease (MELD), tumor-lymph node-metastasis (TNM) staging system, Okuda classification, and CLIP score. A simple assessment using a nomogram showed the 1-year PFS rate of patients with HCC. In the prospective cohort, the KM curve showed that the high TSH level group had a shorter PFS than the low TSH level ( = 0.001).

Conclusion: The prognostic model of HCC progression was superior to other well-known classical tumor scoring systems. A high TSH level was correlated to poor outcome, particularly those with advanced HCC.

Citing Articles

The Clinical Relevance of Hypothyroidism in Patients with Solid Non-Thyroid Cancer: A Tantalizing Conundrum.

Deligiorgi M, Trafalis D J Clin Med. 2022; 11(12).

PMID: 35743483 PMC: 9224934. DOI: 10.3390/jcm11123417.

References

Balachandran V, Gonen M, Smith J, DeMatteo R . Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015; 16(4):e173-80. PMC: 4465353. DOI: 10.1016/S1470-2045(14)71116-7. View

Reddy A, Dash C, Leerapun A, Mettler T, Stadheim L, Lazaridis K . Hypothyroidism: a possible risk factor for liver cancer in patients with no known underlying cause of liver disease. Clin Gastroenterol Hepatol. 2006; 5(1):118-23. DOI: 10.1016/j.cgh.2006.07.011. View

Frau C, Loi R, Petrelli A, Perra A, Menegon S, Kowalik M . Local hypothyroidism favors the progression of preneoplastic lesions to hepatocellular carcinoma in rats. Hepatology. 2014; 61(1):249-59. DOI: 10.1002/hep.27399. View

Durand F, Valla D . Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. J Hepatol. 2005; 42 Suppl(1):S100-7. DOI: 10.1016/j.jhep.2004.11.015. View

Ang S, Ng E, Li H, Ong Y, Choo S, Ngeow J . Correction: The Singapore Liver Cancer Recurrence (SLICER) Score for Relapse Prediction in Patients with Surgically Resected Hepatocellular Carcinoma. PLoS One. 2015; 10(5):e0128058. PMC: 4430280. DOI: 10.1371/journal.pone.0128058. View

Chi H, Tsai C, Tsai M, Yeh C, Lin K . Molecular functions and clinical impact of thyroid hormone-triggered autophagy in liver-related diseases. J Biomed Sci. 2019; 26(1):24. PMC: 6407245. DOI: 10.1186/s12929-019-0517-x. View

Zimmerman M, Ghobrial R, Tong M, Hiatt J, Cameron A, Hong J . Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators. Arch Surg. 2008; 143(2):182-8. DOI: 10.1001/archsurg.2007.39. View

Okada S, Shimada K, Yamamoto J, Takayama T, Kosuge T, Yamasaki S . Predictive factors for postoperative recurrence of hepatocellular carcinoma. Gastroenterology. 1994; 106(6):1618-24. DOI: 10.1016/0016-5085(94)90419-7. View

Llovet J, Montal R, Villanueva A . Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival. J Hepatol. 2019; 70(6):1262-1277. DOI: 10.1016/j.jhep.2019.01.028. View

10.

Zhang X, Song Y, Feng M, Zhou X, Lu Y, Gao L . Thyroid-stimulating hormone decreases HMG-CoA reductase phosphorylation via AMP-activated protein kinase in the liver. J Lipid Res. 2015; 56(5):963-71. PMC: 4409286. DOI: 10.1194/jlr.M047654. View

11.

Pinter M, Haupt L, Hucke F, Bota S, Bucsics T, Trauner M . The impact of thyroid hormones on patients with hepatocellular carcinoma. PLoS One. 2017; 12(8):e0181878. PMC: 5542594. DOI: 10.1371/journal.pone.0181878. View

12.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

13.

Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H . Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985; 56(4):918-28. DOI: 10.1002/1097-0142(19850815)56:4<918::aid-cncr2820560437>3.0.co;2-e. View

14.

Shih Y, Huang Y, Lin K, Chu Y, Yeh C . Identification of Functional Thyroid Stimulating Hormone Receptor and Gene Mutations in Hepatocellular Carcinoma. Anticancer Res. 2018; 38(5):2793-2802. DOI: 10.21873/anticanres.12523. View

15.

Cholongitas E, Papatheodoridis G, Vangeli M, Terreni N, Patch D, Burroughs A . Systematic review: The model for end-stage liver disease--should it replace Child-Pugh's classification for assessing prognosis in cirrhosis?. Aliment Pharmacol Ther. 2005; 22(11-12):1079-89. DOI: 10.1111/j.1365-2036.2005.02691.x. View

16.

Kamath P, Kim W . The model for end-stage liver disease (MELD). Hepatology. 2007; 45(3):797-805. DOI: 10.1002/hep.21563. View

17.

Zhang N, Jin W, Zhou S, Yang J, Harmsen W, Giama N . Hypothyroidism is associated with worse outcomes of hepatocellular carcinoma patients after liver transplantation. Cancer Med. 2018; 7(12):5870-5878. PMC: 6308061. DOI: 10.1002/cam4.1797. View

18.

Talluri R, Shete S . Using the weighted area under the net benefit curve for decision curve analysis. BMC Med Inform Decis Mak. 2016; 16:94. PMC: 4949771. DOI: 10.1186/s12911-016-0336-x. View

19.

Kemp R, Prasad V . Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?. BMC Med. 2017; 15(1):134. PMC: 5520356. DOI: 10.1186/s12916-017-0902-9. View

20.

Schoenberg M, Hao J, Bucher J, Miksch R, Anger H, Mayer B . Perivascular Tumor-Infiltrating Leukocyte Scoring for Prognosis of Resected Hepatocellular Carcinoma Patients. Cancers (Basel). 2018; 10(10). PMC: 6210365. DOI: 10.3390/cancers10100389. View